Felimazole 2.5 mg Coated Tablets for Cats

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Thiamazole

から入手可能:

Dechra Regulatory B.V.

ATCコード:

QH03BB02

INN（国際名）:

Thiamazole

投薬量:

2.5 mg/tablet

医薬品形態:

Coated tablet

処方タイプ:

POM: Prescription Only Medicine as defined in relevant national legislation

治療領域:

thiamazole

認証ステータス:

Authorised

承認日:

2009-02-20

製品の特徴

Health Products Regulatory Authority
15 February 2022
CRN00CCR9
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Felimazole 2.5 mg Coated Tablets for Cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 tablet contains:
ACTIVE SUBSTANCE
Thiamazole 2.5 mg
EXCIPIENTS
Titanium Dioxide (E171) 1.12 mg
Erythrosine (E127) 0.01 mg
Sodium methyl parahydroxybenzoate (E219) 0.0034 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Coated tablet.
Pink sugar-coated biconvex tablets, 5.5 mm diameter.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the stabilisation of hyperthyroidism in cats prior to surgical
thyroidectomy.
For the long term treatment of feline hyperthyroidism.
4.3 CONTRAINDICATIONS
Do not use in cats suffering from systemic disease such as primary
liver disease or diabetes mellitus.
Do not use in cats showing signs of autoimmune disease.
Do not use in animals with disorders of white blood cells, such as
neutropenia and
lymphopenia.
Do not use in animals with platelet disorders and coagulopathies
(particularly thrombocytopenia).
Do not use in cats with hypersensitivity to thiamazole or the
excipient, polyethylene glycol.
Do not use in pregnant or lactating females.
Please refer to section 4.7.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
If more than 10 mg per day is required animals should be monitored
particularly carefully.
Health Products Regulatory Authority
15 February 2022
CRN00CCR9
Page 2 of 5
Use of the product in cats with renal dysfunction should be subject to
careful risk:benefit assessment by the clinician. Due to
the effect thiamazole can have on reducing the glomerular filtration
rate, the effect of therapy on renal function should be
monitored closely as deterioration of an underlying condition may
occur.
Haematology must be monitored due to risk of leucopenia or haemolytic
anaemia.
Any animal that sudd